27 research outputs found

    Intestinal Microbiota in Pediatric Patients with End Stage Renal Disease: A Midwest Pediatric Nephrology Consortium study

    No full text
    Background: End-stage renal disease (ESRD) is associated with uremia and increased systemic inflammation. Alteration of the intestinal microbiota may facilitate translocation of endotoxins into the systemic circulation leading to inflammation. We hypothesized that children with ESRD have an altered intestinal microbiota and increased serum levels of bacterially derived uremic toxins. Methods: Four groups of subjects were recruited: peritoneal dialysis (PD), hemodialysis (HD), post-kidney transplant and healthy controls. Stool bacterial composition was assessed by pyrosequencing analysis of 16S rRNA genes. Serum levels of C-reactive protein (CRP), D-lactate, p-cresyl sulfate and indoxyl sulfate were measured. Results: Compared to controls, the relative abundance of Firmicutes (P = 0.0228) and Actinobacteria (P = 0.0040) was decreased in PD patients. The relative abundance of Bacteroidetes was increased in HD patients (P = 0.0462). Compared to HD patients the relative abundance of Proteobacteria (P = 0.0233) was increased in PD patients. At the family level, Enterobacteriaceae was significantly increased in PD patients (P = 0.0020) compared to controls; whereas, Bifidobacteria showed a significant decrease in PD and transplant patients (P = 0.0020) compared to control. Alpha diversity was decreased in PD patients and kidney transplant using both phylogenetic and non-phylogenetic diversity measures (P = 0.0031 and 0.0003, respectively), while beta diversity showed significant separation (R statistic = 0.2656, P = 0.010) between PD patients and controls. ESRD patients had increased serum levels of p-cresyl sulfate and indoxyl sulfate (P \u3c 0.0001 and P \u3c 0.0001, respectively). The data suggests that no significant correlation exists between the alpha diversity of the intestinal microbiota and CRP, D-lactate, or uremic toxins. Oral iron supplementation results in expansion of the phylum Proteobacteria. Conclusions: Children with ESRD have altered intestinal microbiota and increased bacterially derived serum uremic toxins

    Blood Pressure Outcomes in NICU-Admitted Infants with Neonatal Hypertension: A Pediatric Nephrology Research Consortium Study

    No full text
    Objective To describe the blood pressure outcomes of NICU-admitted infants with idiopathic (non-secondary) hypertension (HTN) who were discharged on antihypertensive therapy. Study Design Retrospective ,multicenter study of 14 centers within the Pediatric Nephrology Research Consortium (PNRC). We included all infants with a diagnosis of idiopathic HTN discharged from neonatal intensive care units (NICU) on antihypertensive treatment. The primary outcome was time to discontinuation of antihypertensive therapy, grouped into ≤6 months, \u3e6 months – 1 year, and \u3e 1 year). Comparisons between groups were made with chi-squared tests, Fisher’s exact tests, and analysis of variance. Results Data from 118 infants (66% male) were included. Calcium channel blockers were the most prescribed class of antihypertensives (56%) in the cohort. The percentages remaining on antihypertensives after NICU discharge were 60% at 6 months, 26% at 1 year, and 7% at 2 years. Antenatal steroid treatment was associated with decreased likelihood of antihypertensive therapy \u3e1 year after discharge. Conclusions This multicenter study reports that most NICU-admitted infants diagnosed with idiopathic HTN will discontinue antihypertensive treatment by 2 years after NICU discharge. These data provide important insights into the outcome of neonatal HTN but should be confirmed prospectively

    Blood Pressure Outcomes in NICU-Admitted Infants with Neonatal Hypertension: A Pediatric Nephrology Research Consortium Study

    No full text
    Objective To describe the blood pressure outcomes of NICU-admitted infants with idiopathic (non-secondary) hypertension (HTN) who were discharged on antihypertensive therapy. Study Design Retrospective ,multicenter study of 14 centers within the Pediatric Nephrology Research Consortium (PNRC). We included all infants with a diagnosis of idiopathic HTN discharged from neonatal intensive care units (NICU) on antihypertensive treatment. The primary outcome was time to discontinuation of antihypertensive therapy, grouped into ≤6 months, \u3e6 months – 1 year, and \u3e 1 year). Comparisons between groups were made with chi-squared tests, Fisher’s exact tests, and analysis of variance. Results Data from 118 infants (66% male) were included. Calcium channel blockers were the most prescribed class of antihypertensives (56%) in the cohort. The percentages remaining on antihypertensives after NICU discharge were 60% at 6 months, 26% at 1 year, and 7% at 2 years. Antenatal steroid treatment was associated with decreased likelihood of antihypertensive therapy \u3e1 year after discharge. Conclusions This multicenter study reports that most NICU-admitted infants diagnosed with idiopathic HTN will discontinue antihypertensive treatment by 2 years after NICU discharge. These data provide important insights into the outcome of neonatal HTN but should be confirmed prospectively

    Utility of the 2018 Revised ISN/RPS Thresholds for Glomerular Crescents in Childhood-Onset Lupus Nephritis: A Pediatric Nephrology Research Consortium Study

    No full text
    Background The revised 2018 ISN/RPS Classification System for lupus nephritis (LN) includes calculations for both activity index (A.I.) and chronicity index (C.I.). Unchanged were the thresholds of \u3c 25%, 25–50%, and \u3e 50% crescents to distinguish between mild, moderate, and severe activity/chronicity. We aimed to evaluate these thresholds for percent crescents in childhood-onset LN. Methods Eighty-six subjects \u3c 21 years of age were enrolled from the Pediatric Glomerulonephritis with Crescents Registry, a retrospective multi-center cohort sponsored by the Pediatric Nephrology Research Consortium. Thresholds of 10%, 25%, and 50% for both cellular/fibrocellular and fibrous crescents were interrogated for primary outcomes of kidney failure, eGFR, and eGFR slope. Results Median age at time of initial biopsy was 14 years (range 1–21). Median follow-up time was 3 years (range 1–11). Cumulative incidence of kidney failure was 6% at 1 year and 10% at latest follow-up. Median eGFR slope was − 18 mL/1.73 m 2 /min (IQR − 51 to + 8) at 1 year and − 3 mL/min/1.73 m 2 /year (IQR − 19 to + 6) at latest follow-up. We found no difference in kidney failure at the proposed \u3c 25% and 25–50% cellular crescents thresholds, and thus added a new provisional threshold of 10% that better predicted outcomes in children. Moreover, use of 10% and 25% thresholds for fibrous crescents showed a fourfold and sevenfold increase in risk of kidney failure. Conclusions In children with crescentic LN, use of 10% and 25% thresholds for cellular crescents better reflects disease activity, while these thresholds for fibrous crescents better discriminates kidney disease outcomes
    corecore